Christian Marsolais, Ph. D.
Senior Vice President and Chief Medical Officer
Dr. Christian Marsolais has been Senior Vice President and Chief Medical Officer since June 2016. He joined Theratechnologies in 2007. He brings more than 30 years of experience in the research, development and commercialization of new drugs.
He started his career working for global pharmaceutical companies, including Sandoz (now Novartis), Biochem and Pfizer. Prior to joining Theratechnologies, he was part of the global oncology team at Pfizer.
Dr. Marsolais led the medical team which was central to the approval of Egrifta® by the Food and Drug Administration in the United States. He was also instrumental in the efforts that led to the acquisition of the commercial rights to Trogarzo® in the United States and Europe and its subsequent approval. He was also closely involved in the acquisition of Katana Biopharma Inc., which discovered the SORT1+ Technology™. In addition, he is responsible for the development of tesamorelin for the potential treatment of NASH.
Dr. Marsolais holds a Ph.D. in biochemistry from the Université de Montréal.